Literature DB >> 28782469

Immune Checkpoint Inhibitors: Basics and Challenges.

Bin Li1, Ho Lam Chan1, Pingping Chen1.   

Abstract

Cancer is one of the most deadly diseases in the modern world. The last decade has witnessed dramatic advances in cancer treatment through immunotherapy. One extremely promising means to achieve anti-cancer immunity is to block the immune checkpoint pathways - mechanisms adopted by cancer cells to disguise themselves as regular components of the human body. Many review articles have described a variety of agents that are currently under extensive clinical evaluation. However, while checkpoint blockade is universally effective against a broad spectrum of cancer types and is mostly unrestricted by the mutation status of certain genes, only a minority of patients achieve a complete response. In this review, we summarize the basic principles of immune checkpoint inhibitors in both antibody and smallmolecule forms and also discuss potential mechanisms of resistance, which may shed light on further investigation to achieve higher clinical efficacy for these inhibitors. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CTLA-4; Immunotherapy; PD-1; T cells; checkpoint blockade; resistance.

Mesh:

Substances:

Year:  2019        PMID: 28782469     DOI: 10.2174/0929867324666170804143706

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  88 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  Mining the prognostic significance and immune infiltration of STAT family members in human breast cancer by bioinformatics analysis.

Authors:  Yudong Zhou; Siyuan Jiang; Shibo Yu; Lizhe Zhu; Yang Liu; Shouyu Li; Na Hao; Yu Ren
Journal:  Gland Surg       Date:  2022-04

Review 3.  Advances in plant-derived natural products for antitumor immunotherapy.

Authors:  Yi Yang; Qinying Liu; Xianai Shi; Qiuhong Zheng; Li Chen; Yang Sun
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

4.  Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction.

Authors:  Kuang XiaYu; Cai GuoGang; Li CanXuan; Xie WeiBin
Journal:  Dis Markers       Date:  2022-06-06       Impact factor: 3.464

5.  Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.

Authors:  Kang Miao; Li Zhang
Journal:  Interdiscip Sci       Date:  2021-06-21       Impact factor: 2.233

Review 6.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

7.  Establishment of a novel double-monoclonal antibody sandwich enzyme-linked immunosorbent assay (ELISA): tool for human B7-H4 detection in autoimmune diseases.

Authors:  Sisi Ding; Hengxin Zhou; Yanzheng Gu; Yu Shen; Li Zhang; Huayang Zhao; Jian Wu; Xueguang Zhang; Xin Chang; Cuiping Liu
Journal:  Clin Exp Immunol       Date:  2021-06-06       Impact factor: 5.732

Review 8.  Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation.

Authors:  Chris M Li; Zhibin Chen
Journal:  Front Cell Dev Biol       Date:  2021-06-21

Review 9.  Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy.

Authors:  Huixian Zhang; Wencheng Zhao; Xingya Li; Yayi He
Journal:  Onco Targets Ther       Date:  2021-06-21       Impact factor: 4.147

Review 10.  Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer.

Authors:  Shelby N Bess; Gage J Greening; Timothy J Muldoon
Journal:  Cytokine Growth Factor Rev       Date:  2019-10-24       Impact factor: 17.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.